

### Eric Alexander Secensky, MD, FACC Director of Vascular Intervention; Assistant Professor of Medicine

#### Printed as of 4/18/2024

# Disclosures

| Personal Commercial (20)         |                           |                          |   |
|----------------------------------|---------------------------|--------------------------|---|
| Company Name                     | Relationship Category     | Compensation Level       | Topic Area(s)                                       |
| Self                             |                           |                          |   |
| Abbott Laboratories              | Consultant Fees/Honoraria | Significant (>= \$5,000) |   |
| AstraZeneca Pharmaceuticals      | Research/Research Grants  | Significant (>= \$5,000) |   |
| Bayer Healthcare Pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) |   |
| BD Bard                          | Speaker's Bureau          | Modest (< \$5,000)       |   |
| BD Bard                          | Research/Research Grants  | Significant (>= \$5,000) |   |
| Boston Scientific                | Consultant Fees/Honoraria | Significant (>= \$5,000) |   |
| Boston Scientific                | Research/Research Grants  | Significant (>= \$5,000) |   |
| Cook                             | Speaker's Bureau          | Significant (>= \$5,000) |   |
| Cook                             | Research/Research Grants  | Significant (>= \$5,000) |   |
| CSI                              | Research/Research Grants  | Significant (>= \$5,000) |   |
| CSI                              | Consultant Fees/Honoraria | Significant (>= \$5,000) |   |
| Endovascular Engineering         | Consultant Fees/Honoraria | Significant (>= \$5,000) | Pulmonary Hypertension and Venous<br>Thromboembolic |
| Inari                            | Consultant Fees/Honoraria | Modest (< \$5,000)       |   |
| Janssen Pharmaceuticals, Inc     | Consultant Fees/Honoraria | Significant (>= \$5,000) |   |
| Laminate Medicial                | Research/Research Grants  | Significant (>= \$5,000) | Vascular Medicine                                   |
| Medtronic                        | Research/Research Grants  | Significant (>= \$5,000) |   |
| Medtronic                        | Consultant Fees/Honoraria | Significant (>= \$5,000) |   |
| Philips                          | Consultant Fees/Honoraria | Significant (>= \$5,000) |   |
| Philips                          | Research/Research Grants  | Significant (>= \$5,000) |   |
| Venture Medical Group            | Consultant Fees/Honoraria | Significant (>= \$5,000) |   |

# Additional Personal Commercial Disclosures for Education Activities (0)

| Non-Commercial Enity Name                            | Relationship Category        | Compensation Level   | Topic Area(s) |
|--|------------------------------|----------------------|---------------|
| Self   |                              |                      |               |
| Baim Institute                                       | Data Safety Monitoring Board | Modest (< \$5,000)   |               |
| Clinical Trial Enroller (3                           | )                            |                      |               |
| Clinical Trial Enroller (3                           | )                            |                      |               |
|  | )<br>Trial Sponsor           | Trial Funding Source |               |
| Clinical Trial Enroller (3<br>Trial Name<br>LightLab |                              | Trial Funding Source |               |
| Trial Name   | Trial Sponsor                | Trial Funding Source |               |

# Institutional Financial Decision-Making Role (3)

No disclosures on record

| Funding Source | Institutional Compensation Level |
|----------------|----------------------------------|
| FDA            | Significant (>= \$5,000)         |

Funding Source

NHLBI/NIH K23HL150290

University of California, San Francisco

#### Expert Witness Testimony (0)

No disclosures on record

*†* Commercial Funding Source | *‡* Trial Name

#### Agreement

#### Certified Education Attestation | Signed on 5/5/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

#### Confidentiality, Disclosure and Assignment Agreement | Signed on 5/5/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 5/5/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 4/6/2024

#### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.



Significant (>= \$5,000)

Significant (>= \$5,000)